Rhupus: Illustration about four Senegalese Cases

Ndao A.C.¹, Diallo R², Diagne N.³, Kane B.S.⁴, Djiba B.⁵, Dieng M.⁶, Faye A.⁷, Ndongo S.⁸, Diallo S.⁹, Pouye A.¹⁰

1, 2, 3, 4, 5, 6, 7, 8, 10 Department of Internal Medicine

⁹Department of Rheumatology

Abstract: Introduction: Rhupus is a combination of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). It is a rare entity whose existence is often controversial. Since its first description in 1971 by Schur, fewer than 150 cases have been described in the literature. We are reporting four observations. Materials and methods: A retrospective study, carried out between August 2011 and March 2014 in the Department of Internal Medicine at the University Hospital Aristide Le Dantec, was used to collect the observations of patients with rhupus. The diagnosis of RA and SLE was based on epidemiological, clinical and paraclinical arguments in accordance with the ACR / EULAR 2010 criteria for PR and ACR 1997 for SLE. Observations: Four observations were collected in 2 women and 2 men of average age 33 years (extremes: 28 years and 36 years). They all had chronic polyarthritis (1 to 10 years of evolution), polysynovial, and peripheral with irreducible deformations in 3 patients with ulnar stroke type, ankylosis of the wrists and buttonhole. The extra-articular manifestations were rheumatoid nodules (1 case) and an erythema malar in vespertilio and decollete (1 case). A nonspecific biological inflammatory syndrome was present in all patients. Two patients had lymphopenia at 1176 and 1220 / mm3. On the immunological level, there was a positivity of rheumatoid factors (1 case), anti-nuclear (1 case with speckled fluorescence), anti-CCP antibodies (3 cases), anti-RNP antibodies (3 cases) Anti-SmRNP (3 cases), and anti-Sm (3 cases), anti-SSA / Ro and SSB / La (1 case). The standard X-ray showed a demineralization of the bones of the carpus and epiphyseal in bands (1 case), a radio carpal pinching (2 cases) and proximal interphalangeal (2 cases), a carpite (3 cases), an erosion of the head of proximal phalanges and metacarpals (3 cases). Radiography of the hands and feet was normal in one patient. A therapeutic management combined low-dose of corticosteroids (4 cases), hydroxychloroquine (4 cases) and methotrexate (3 cases). The progression was favorable in 2 patients, one had persistent monoarthritis moderately responding to infiltration and one patient was lost from view. <u>Conclusion</u>: Although rarely reported in the literature, the association of rheumatoid arthritis and lupus remains a reality. Thus, in the face of any systemic pathology, attention must be paid to the other associated autoimmune diseases.

Keywords: rheumatoid arthritis, lupus, rhupus, anti-CCP, anti-Sm

1. Introduction

The coexistence of two or more systemic diseases in the same patient is possible but infrequent. The association of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) called rhupus, the existence of which remains controversial, is all the more rare. Its prevalence is estimated at 0.09%[1]. Since the first observation reported by Toone in 1960 [2] and its first description in 1971 by PH Schur [3], fewer than 150 cases have been described in the literature. We are reporting four observations.

2. Observations

Observation 1: This is a 33-year-old patient received in consultation in August 2011, in the internal medicine department of the Aristide Le Dantec Hospital of Dakar University Hospital, for peripheral chronic joint pain, evolving over the past 10 years, interesting the metacarpal-phalangeal (MCP), proximal interphalangeal (IPP), metacarpalphalangeal (MTP), wrists, ankles, elbows, shoulders, knees with involvement of the cervical spine. This arthritis was bilateral, symmetrical, evolving by thrust and remission.

She was attended the department of dermatology, from the same hospital, from 1997 to 1998, for a lupus disease. She had been put on prednisone and hydroxychloroquine and then she discontinued this treatment without medical advice after a year.

Physical examination had shown the presence of synovitis at the ankles and PPIs of the hands, a skeletal test positive for MCP, deformities of the type of bilateral ulnar stroke and buttonhole at the 3rd radius. The extra-articular signs were made of erythema malar in vespertilioand erythema at the decollete (anterior face of the thorax).

Biology revealed a non-specific biological inflammatory syndrome (SIBNS) with a rate of sedimentation (SV) at 50mm at the first hour, a C-reactive protein (CRP) at 32mg / L, anemia (hemoglobin = 9.4 g / dl) microcytic hypochrome. White blood cells were at 7 800 / mm3 (neutrophils at 4 000 / mm3, lymphocytes at 4200 / mm3), the platelet count was 318 000 / mm3. The 24-hour proteinuria was 0.03 g. Transaminases, urea and serum creatinine were normal. The serology of viral hepatitis B and C was negative.

At immunology, Waaler Roses' reaction was positive at 36 IU / mL, anti-CCP antibodies were positive at 69 IU / mL (N < 5). However, anti-RNP, anti-Sm, anti-SSA and anti-SSB antibodies were negative. Native anti-DNA and anti-nuclear antibodies were not searched.

The X-ray of the faced hands showed a pinching of the joint spacing to the PPIs, the erosions and geodes to the 3rd PPI. Thus the diagnosis of rhupus was retained in front of this chronic, erosive, deforming polyarthritis associated with a positivity of the anti-CCP in a young woman. Treatment based on methotrexate, hydroxychloroquine and prednisone was instituted with a good evolution.

Observation 2: Patient of 36 years, followed in the same department since October 2012, for polysynovial, chronic, bilateral, symmetrical, peripheral, non-deforming polyarthritis reaching the PPI, MCP, wrist, ankle, shoulders and left knee without extra-articular signs and evolving for 1 year.

Biology had demonstrated an acceleration of SV at 30 mm, normal CRP at 3.1 mg / L, anemia at 10.6 g / dl, microcytic hypochromium. Leukocytes were at 4,200 / mm3 and platelets at 338,000 / mm3. The 24-hour proteinuria was absent. Transaminases, serum creatinine were normal and the serology of viral hepatitis B was negative.

X-rays of the hands, feet and thorax were normal.

Immunological analyzes showed a positivity of anti-CCP antibodies at 148 IU / mL, anti-U1 RNP at 1.8 IU / mL, anti-Sm RNP greater than 8 IU / mL and anti-Sm at 3.1 IU / ML. Thus the diagnosis of rhupus was made in front of the chronic polyarthritis, the normal CRP and the results of the immunology.

The evolution, under Methotrexate, folic acid, prednisone and hydroxychloroquine, was marked by the persistence of monoarthritis of the right wrist responding moderately to infiltration.

Observation 3: 28-year-old patient received in May 2013 for chronic, bilateral, symmetrical polyarthritis, evolving by spontaneous relapses and relapses, involving wrists, MCPs, IIPs (hands), PDIs, IPDs, elbows, shoulders and knees. Physical examination noted deformities in the form of bilateral ulnar wobbling and extra-articular signs with rheumatoid nodules at the elbows. It had a SIBNS with an SV at 34 mm at the first hour, a CRP at 96 mg / L, an anemia at 8.2 g / dL normocytic hypochrome. Lymphopenia

at 1 176 / mm3 was noted. Leukocytes, neutrophils, platelets, transaminases and the serum creatinine were normal. The serology of viral hepatitis B was negative.

The antibody assay showed a negativity of rheumatoid factors, anti-CCP, native anti-DNA and a positivity of U1 RNP greater than 8UI / mL, Sm RNP greater than 8UI / mL and Sm greater than 8UI / mL

The X-ray of the hands showed a demineralization in epiphyseal band and carps, a left wrist radiograph and IPP with head erosion of the right 5th IPP.

The diagnosis of rhupus was retained based on erosive arthritis, rheumatoid nodules, lymphopenia, and high anti-Sm positivity.

He had been put on hydroxychloroquine and prednisone but the treatment could not be evaluated because he was loss of sight of. He was not on methotrexate for his fear of side effects on fertility.

Observation 4: This was a 35-year-old man, followed since March 2014 for chronic polyarthritis, peripheral to large and small joints with presence of synovitis, deforming to the left ulnar wing type, ankylosis of the wrists and buttonhole to the 3rd and 4th rays to the left. This table had evolved a year before its first consultation. The extra-articular signs consisted of lesions of vitiligo at the back level.

In the presence of chronic, peripheral, deforming, erosive polyarthritis, lymphopenia, the positivity of anti-CCP and anti-Sm; the diagnosis of rhupus was retained. He was put on methotrexate, folic acid, hydroxychloroquine and prednisone with a favorable development.

Observation	1	2	3	4
Sex	Female	Female	Male	Male
Age	33 years	36 years	28 years	35 years
Signs and joints	Chronic polyarthritis (10	Non-deforming	Chronic polyarthritis (4 years)	Chronic polyarthritis (1
	years) peripheral	polysynovial peripheral	peripheral polysynovial with	year) peripheral
	polysynovial erosive	chronic polyarthritis (1 year)	hand of Jacoud	polysynovial erosive
Extra-articular signs	- Erythema malar in	Nil	Rheumatoid nodules	Back vitiligo lesions
	vespertilio			
	-Decreased erythema			
VS (mm/H1)	50	30	34	Not done
CRP (g/dl)	32	3,1	96	Not done
Hemoglobin	Hb: 9.4 g / dl microcytic	Hb: 10.6 g / dl microcytic	- Hb: 8.2 g / dl hypochrome	Lymphopenia at 1220 /
	hypochrome	hypochrome	normocytic	mm3
			- Lymphocytopenia at 1176/ mm3	
Rheumatoid Factors	WR:36UI/ml	Not done	Negative	Not done
Anti-CCP	69 UI/ml	148 UI/ml	Negative	200 UI/ml
ANA	Not done	Not done	Not done	1/640, speckled
				appearance
Anti-ECT (U1RNP,		U1RNP > 8 UI/ml	U1RNP > 8 UI/ml	U1RNP 3,2
SmRNP, Sm, SSA / Ro,		SmRNP > 8 UI/ml	SmRNP > 8 UI/ml	Sm > 8
SSB / La, Jo1, Scl70,		Sm : 3,1 UI/ml	Sm > 8 UI/ml	SSA/Ro 3
centromeres)				SSB/La 2,6
Anti-DNAn	Not done	Note done	Negative	Not done
			Demineralization of carp bones	
	Pinching of PPI		and epiphyseal band	
Radiography of hands	interlining	normal	- Carpal tunneling	Bilateral carpite
and feet	Erosion and geodesy at		- Head Erosion at the right 5th	
	the 3rd IPP		IPP	

Table 1: Clinical and paraclinical manifestations of the rum of the 4 patients

Volume 6 Issue 8, August 2017

www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

3. Discussion

Rhupus is defined by the association of erosive deforming peritoneal arthritis of RA with clinical signs of SLE with the presence of autoantibodies specific for these two conditions (rheumatoid or anti-CCP factors for RA and anti- DNAn or anti-Sm for the LES) [4]. It is a rare entity whose existence is often controversial.

Our series reports the presence of a rhupus in two women and two men. However, unlike our series, the clear female predominance of this syndrome has been reported in several publications [5, 6]

This could be explained by the small number of our series.

The average age of our patients was 33 years, which is consistent with the data found in the literature. Indeed, rhupus mainly concerns the young woman in the third decade [7, 8, 9]

This could be explained by the small number of our series.

In the majority of cases, the diagnosis of RA was made concurrently with the diagnosis of lupus. PR may precede lupus, car studies in the production of anti-nuclear antibodies in patients followed prolonged for RA [10].

Simon et al. [11] demonstrated that patients with rheumatoid arthritis had first manifestations of RA and then, on average, 4 years later, clinical signs and biological abnormalities appeared in favor of SLE.

In the study by Sparsa et al. [6], RA pre-dicted the diagnosis of lupus in ten cases; whereas in 6 patients the diagnosis of rhupus was concomitant. The predominant signs of RA were erosive arthritis and rheumatoid nodules, whereas LES manifestations were generally minor, such as photosensitivity, hematological abnormalities [12]. In the largest cohort on rhupus with 28 patients, only one had proliferative type III glomerulonephritis and two had proteinuria greater than 0.5 g / 24 h and no other visceral or haematological involvement was found [6]. However, more severe manifestations of SLE have been reported [13, 14].

The clinical manifestations of rhupus in our patients were mainly articular and cutaneous. Polyarthritis is one of the most frequent clinical manifestations of lupus [15, 16] and RA. However, it is classically non-erosive during SLE, whereas RA is characterized by the early onset of erosions [17]. Cases of deforming and erosive SLE were nevertheless reported in approximately 5% of patients followed for SLE [18, 19]. Only one patient presented clinical signs suggestive of lupus with malar erythema. Visceral involvement is rarely described [14].

In our series (Table I), only one patient showed no destructive lesions on the standard X-ray of the pathways and feet, knowing that she was seen in an evolution and that the articular ultrasound neither the dedicated MRI was realized on her in order to formally eliminate erosion. It has been reported that most patients with RA develop erosive arthritis after two or three years of development [17]

All other cases met the diagnostic criteria of rhupus and were consistent with the literatures' data.

On the paraclinic level, 3 of our patients showed immunological signs suggestive of lupus associated with RA with positive anti-CCP and anti-Sm (the latter being strongly suggestive of lupus).

The antibodies anti-peptides cyclic citrullinated (CCP) are classically considered as a diagnostic marker of high sensitivity and specificity in RA [20, 21]. However, recent work has shown that anti-CCPs can be detected in other conditions [22, 23] and in particular Sjögren's syndrome [24] and SLE [25, 26]. The presence of these antibodies in these diseases, especially in SLE, is a predictive serum marker for early and erosive polyarthritis [22, 26, 27]

4. Conclusion

Rhupus is a rare but real entity. To the question "rhupus myth or reality? ", A formal response will be difficult to make. Is it a SLE with a deforming erosive polyarthritis sometimes (Jaccoud's rheumatism) and anti-CCP positivity or actually a PR and SLE overlap syndrome? It can be considered as a real entity insofar as a high anti-CCP antibodies level greater than 50 IU / mL is specific for RA.

5. Conflicts of Interest

None

References

- Panush RS., Edwards NL., Longley S., Webester E. Rhupus syndrome. Archives of Internal Medicine 1988; 148:1633-1636
- [2] Toone E, Irby R, Pierce EL. The cell LE in rheumatoid arthritis. American Journal of Medicine Sciences 1960; 240:599–608]
- [3] Schur PH. Systemic lupus erythematosus in Cecil-Loeb Texbook of Medicine Beeson PB, McDermott W (eds) Philadelphia, PA 1971, p 821
- [4] Amezcua-Guerra LM., Spingall R., Marquez-Velasco R. et al. Presence of antibodies against cyclic citrullinated peptides in patients with "rhupus": a crosssectional study. ArthritisResearch and Therapy2006; 8 : R144]. Il s'agit d'une entité
- [5] Sordet C., Ardizzone M., El Bouchti I. et al. Efficacité et tolérance de l'etanercept dans le rhupus.Rev Rhum 2006; 73: 1089–1259;
- [6] Sparsa L., Sordet C., Chatelus E. et al. Caractéristiques clinicobiologiquesetradiologiques du rhupus : résultats d'une cohorte de 28 patients RevMéd interne. 2010; 31S: S84–S193
- [7] Tani C., D'Aniello D., Delle Sedie A. et al. Rhupus syndrome: Assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. Autoimmunity Reviews 2013; 12: 537–541;
- [8] Sharma B. "Rhupus: report of 3 cases," Journal of Indian Rheumatology Association, 2003; 11: 51–54.

Volume 6 Issue 8, August 2017

<u>www.ijsr.net</u>

Licensed Under Creative Commons Attribution CC BY

- [9] Andrade-Ortega L.,Irazoque-Palazuelos F., Munóz-López S., Rosales-Don Pablo V.M. Efficacy and Tolerability of Rituximab in Patients With Rhupus ReumatolClin. 2013; 9(4): 201–205
- [10] Nicoloudi A., Renaudineau Y., Devauchelle V., Saraux A., Youinou P. Apport des nouveaux examens biologiques au diagnostic de la polyarthrite rhumatoïde. Immuno-analyse et biologie spécialisée 2007 ; 22 : 167– 172
- [11] Liu T., Li G., Mu R.and Li Z. Clinical and laboratory profiles of rhupus syndrome in a Chinese population: a single-centre study of 51 patients. Lupus2014; 23: 958
- [12] Fernantez A, Quintana G, Rondón F et al. Lupus arthropathy: historicalevolutionfromdeformingarthritis to rhupus. *ClinicalRheumatology*2004; 23:523–526;
- [13] L. Rais, Y. Ben Ariba, L. Ben Fatma et al. Atteinte rénale au cours d'un rhupus syndrome : à propos d'une observation RevMéd Int. 2013 ; 34S : A85–A186
- [14] Ka MM., Diallo S., Kane A. et al. Lupus érythémateux systémique au SénégalMédecine d'Afrique Noire : 1998, 45 (1);
- [15] Diop MM., Gueye YA., Lèye A. et al. Les modes de révélation du lupus érythémateux systémique à Dakar (Sénégal): à propos d'une série de 161 cas. RAFMI 2014; 1(2): 1-44
- [16] Bukhari M., Harrison B., Lunt M. et al. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum 2001; 44: 1248-53
- [17] Cohen M., Steiner G., Smolen J., Isenberg DA.: Erosive arthritis in systemic lupus erythematosus: analysis of a distinct clinical and serologic subset. British Journal of Rheumatology 1998; 37: 421-4
- [18] Schellekens GA., Visser H., de Jong BA. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43: 155-63
- [19] Zeng X., Ai M., Tian X. et al. Diagnostic value of anticycliccitrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol 2003;30: 1451-5.
- [20] Goeb V., Jouen F., Gilbert D. et al. Intérêt diagnostique et pronostique des anticorps dirigés contre les peptides citrullinés. Rev Rhum. 2009 ; 76 (4) ; 626-633.
- [21] Kasapçopur O., Altun S., Aslan M. et al. Diagnostic accuracy of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1687–9.
- [22] Gottenberg JE., Mignot S., Nicaise-Rolland P. et al.Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren'ssyndrome.Ann Rheum Dis 2005;64:114–7
- [23] Korendowych E., Owen P., Ravindran J. et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology (Oxford) 2005; 44(8); 1056-60
- [24] Mediwake R., Isenberg DA., Schellekens GA., Van Venrooij WJ. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. *Annals of Rheumatic Disease* 2001; 60: 67-8
- [25] Chan M., Owen P., Dunphy J. et al. Associations of erosive arthritis with anti-cyclic citrullinated peptide

Volume 6 Issue 8, August 2017

<u>www.ijsr.net</u>

Licensed Under Creative Commons Attribution CC BY

DOI: 10.21275/ART20175849

antibodies and MHC class II alleles in systemic lupus erythematosus. J Rheumatol. 2008; 35: 77-83.

- [26] Zhao Y., Li J., Li XX. et al. What can we learn from the presence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus? *Joint BoneSpine*2009; 76: 501-7
- [27] Hoffman IE., Peene I., Cebecauer L. et al. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. *Annals of Rheumatic Disease*2005; 64:330-2